ClearPoint Neuro, Inc. CLPT
We are a commercial-stage medical device company, incorporated in 1998 as a Delaware corporation, that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. From our inception in 1998, we have deployed significant resources to fund our efforts to develop the foundational capabilities for enabling magnetic resonance imaging ("MRI") guided interventions, building an intellectual property portfolio, and identifying and building out commercial applications for the technologies we develop. In 2021, our efforts expanded beyond the MRI suite to encompass development and commercialization of neurosurgical device products for the operating room setting, as well as consulting services for pharmaceutical companies.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $37.0M | $31.4M | $24.0M | $20.6M | $16.3M | $12.8M | $11.2M | $7.4M | $7.4M | $5.7M |
| Cost of revenue | $14.3M | $12.3M | $10.3M | $7.0M | $5.2M | $3.7M | $3.9M | $2.4M | $2.9M | $2.6M |
| Gross profit | $22.7M | $19.1M | $13.6M | $13.5M | $11.1M | $9.1M | $7.3M | $4.9M | $4.5M | $3.1M |
| R&D | $13.9M | $12.4M | $11.7M | $10.9M | $9.3M | $4.7M | $2.8M | $2.3M | $2.8M | $2.6M |
| SG&A | $16.5M | $12.0M | $11.8M | $9.6M | $8.0M | $5.3M | $4.3M | $4.3M | $4.0M | $4.2M |
| Operating income | -$24.2M | -$19.7M | -$22.4M | -$16.3M | -$13.4M | -$6.2M | -$4.6M | -$5.2M | -$6.3M | -$7.5M |
| Interest expense | $2.4M | $518.0K | $386.0K | $81.0K | $973.0K | $1.4M | $955.0K | $980.4K | $872.9K | $1.1M |
| Pre-tax income | -$25.5M | -$18.9M | -$22.1M | -$16.4M | -$14.4M | -$6.8M | — | — | — | — |
| Income tax | $55.0K | $12.0K | $8.0K | $0 | $0 | $0 | — | — | — | — |
| Net income | -$25.5M | -$18.9M | -$22.1M | -$16.4M | -$14.4M | -$6.8M | -$5.5M | -$6.2M | -$7.2M | -$8.1M |
| EPS, basic | -0.90 | -0.70 | -0.90 | -0.68 | -0.69 | — | — | — | — | — |
| EPS, diluted | -0.90 | -0.70 | -0.90 | -0.68 | -0.69 | -0.43 | -0.42 | -0.56 | -0.93 | -2.93 |
| Shares, diluted (wtd. avg.) | 28.3M | 27.0M | 24.6M | 24.2M | 20.7M | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $45.9M | $20.1M | $23.1M | $27.6M | $54.1M | $20.1M | $5.7M | $3.1M | $9.3M | $3.3M |
| Short-term investments | — | — | $0 | $9.9M | $0 | — | — | — | — | — |
| Receivables | $6.5M | $4.7M | $3.2M | $2.7M | $2.3M | $1.9M | $1.1M | $1.2M | $949.4K | $865.9K |
| Inventory | $8.4M | $6.9M | $7.9M | $9.3M | $4.9M | $3.2M | $3.2M | $2.1M | $2.3M | $1.8M |
| Total current assets | $63.6M | $33.4M | $36.2M | $51.2M | $61.9M | $25.5M | $10.4M | $6.7M | $12.7M | $6.1M |
| Property, plant and equipment | $2.6M | $2.0M | $1.4M | $806.0K | $539.0K | $319.0K | $447.0K | $377.7K | $267.7K | $328.2K |
| Goodwill | $7.5M | $0 | — | — | — | — | — | — | — | — |
| Other intangibles | $13.9M | $0 | — | — | — | — | — | — | — | — |
| Total assets | $97.7M | $39.2M | $42.7M | $55.5M | $65.6M | $29.5M | $11.9M | $7.9M | $13.9M | $7.4M |
| Accounts payable | $1.3M | $1.3M | $393.0K | $272.0K | $427.0K | $300.0K | $966.0K | $500.9K | $759.4K | $1.5M |
| Total current liabilities | $10.8M | $10.4M | $7.4M | $6.8M | $4.8M | $3.2M | $3.8M | $1.9M | $4.4M | $3.0M |
| Long-term debt | $49.1M | — | $9.9M | $9.9M | $9.8M | $21.3M | $2.1M | $3.5M | $4.9M | $4.5M |
| Total liabilities | $69.7M | $13.8M | $21.5M | $18.6M | $16.8M | $27.1M | $7.3M | $6.3M | $8.1M | $8.2M |
| Retained earnings | -$216.9M | -$191.4M | -$172.5M | -$150.4M | -$133.9M | -$119.5M | -$112.7M | -$107.2M | -$101.0M | -$93.9M |
| Total equity | $28.0M | $25.4M | $21.2M | $36.9M | $48.8M | $2.4M | $4.6M | $1.5M | $5.8M | -$756.1K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$23.9M | -$8.9M | -$13.7M | -$16.2M | -$12.7M | -$7.8M | -$2.9M | -$4.6M | -$6.0M | -$5.8M |
| Depreciation and amortisation | $814.0K | $980.0K | $626.0K | $244.0K | $159.0K | $334.0K | $144.0K | $109.4K | $116.5K | $155.7K |
| Stock-based compensation | $8.2M | $6.9M | $6.1M | $4.1M | $2.1M | $1.1M | $799.0K | $1.2M | $1.2M | $1.2M |
| Capital expenditure | $522.0K | $275.0K | $717.0K | $253.0K | $168.0K | $41.0K | $10.0K | $63.5K | $26.8K | $101.0K |
| Investing cash flow | $615.0K | -$275.0K | $8.9M | -$10.7M | -$168.0K | -$482.0K | -$160.0K | -$63.5K | -$26.8K | -$101.0K |
| Financing cash flow | $50.2M | $6.2M | $296.0K | $409.0K | $46.9M | $22.7M | $5.6M | -$1.5M | $12.0M | $3.8M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-151345.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.7M | $7.4M | $7.4M | $11.2M | $12.8M | $16.3M | $20.6M | $24.0M | $31.4M | $37.0M |
| Gross profit | $3.1M | $4.5M | $4.9M | $7.3M | $9.1M | $11.1M | $13.5M | $13.6M | $19.1M | $22.7M |
| Net income | -$8.1M | -$7.2M | -$6.2M | -$5.5M | -$6.8M | -$14.4M | -$16.4M | -$22.1M | -$18.9M | -$25.5M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
- Results announced Item 2.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 3841
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| SYK | STRYKER CORP | $117.81B | 36.6x | 11.2% |
| MMM | 3M CO | $89.46B | 28.9x | 1.5% |
| BSX | BOSTON SCIENTIFIC CORP | $66.22B | 23.6x | 19.9% |
| BDX | BECTON DICKINSON & CO | $54.18B | 34.2x | 8.2% |
| RMD | RESMED INC | $36.48B | 24.2x | 9.9% |
| DXCM | DEXCOM INC | $29.41B | 37.3x | 15.6% |
| MDLN | Medline Inc. | $29.20B | — | 11.5% |
| WST | WEST PHARMACEUTICAL SERVICES INC | $27.60B | 57.8x | 6.3% |